Controlled trial – Page 28 – Communicable Diseases Research

Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation

Research

Published on 2020-09-292022-11-01
Journal: Critical Care [Category] COVID-19, SARS,

The impact of eHealth group interventions on the mental, behavioral, and physical health of adults: a systematic review protocol

Protocol

Published on 2020-09-232022-10-28
Journal: Systematic Reviews [Category] Coronavirus, SARS,

Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark

Letter

Published on 2020-09-172022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 24 hour Administered administration age All participant allergy anti-cytokine therapy approved asked Bacterial infection BCG BCG vaccination blinded to treatment block Bone marrow Chemotherapy component Controlled trial COVID-19 COVID-19 pandemic criteria cumulative current daily dose Day defined Denmark Direct dissemination dose Effect element eligible ENhance EudraCT excluded exclusion group HCW Health care Health care worker HIV-1 hospital Hospital admission hospitals Human immunodeficiency virus Immunocompromised immunodeficiency incidence Inclusion infected with SARS-CoV-2 Infection infections Infectious disease injection Intervention intravenous lymphoma malignancy Medicine meet morbidity and mortality mycobacterial Mycobacterium tuberculosis NaCl solution non-specific not blinded number participant physician Placebo Prednisone Prevent protective effect protocol random randomisation randomised randomised controlled trial receive recruit reduce reductions in Registered reported resuspended Sample secondary Serious Adverse Event severity of COVID-19 Sex solid organ transplantation steroid Stratification study participant Study protocol subject subjects susceptibility suspicion Treatment Trial Tuberculosis Vaccine Vaccines website
[DOI] 10.1186/s13063-020-04714-3 PMC 바로가기 [Article Type] Letter

The use of corticosteroids for COVID-19 infection

Review

Published on 2020-09-162022-10-28
Journal: African Journal of Thoracic and Critical Care Medicine [Category] COVID-19,

Selenium and selenoproteins in viral infection with potential relevance to COVID-19

COVID-19와 잠재적 관련성이 있는 바이러스 감염의 셀레늄 및 셀레노단백질

Review

Published on 2020-09-102022-09-10
Journal: Redox Biology [Category] SARS, 치료제,

[키워드] adaptive Adaptive immunity association benefit Chinese patient Chinese patients contribute Controlled trial COVID-19 COVID-19 patient COVID-19 patients COVID-19-associated inflammation Culture cure rate cytokine Cytokine activation doses Ebselen ENhance ER stress evade example explain expression functions Health Host host immunity host response hosts IL-6 immune response Immunity in viral incidence increased expression Infection inhibit SARS-CoV-2 inhibitor involved linear maturation mechanism mediator metabolite morbidity morbidity and mortality Pathogenesis pathogenic pharmacological play roles positive potential benefit potential benefits Prevent Proteases PROTECT Protective provide randomised rationale Recognition Redox-active selenium species reduced reducing required RNA SARS-CoV-2 SARS-CoV-2 infected cell SARS-CoV-2 infected cells SARS-COV-2 infection SARS-CoV-2 protease Selenium selenoprotein Selenoproteins serum sample serum samples severity significantly significantly higher Trace element Viral viral infections viral pathogenesis virus viruses with COVID-19
[DOI] 10.1016/j.redox.2020.101715 PMC 바로가기 [Article Type] Review

A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for LIving FEtuses (ILIFE) trial

미분화 결합 조직 질환이 있는 여성의 반복적인 임신 상실을 치료하기 위한 하이드록시클로로퀸 및 저용량 프레드니손의 3군, 다기관, 공개 라벨 무작위 대조 시험: LIFE(LIFE) 시험을 위한 면역억제 요법에 대한 프로토콜

Study Protocol

Published on 2020-09-092022-09-10
Journal: Trials [Category] SARS, 임상,

[키워드] abortion Activation addition Anticoagulant anticoagulation Arm assigned connective tissue connective tissue disease Controlled trial defined disease Efficacy eligible patient evaluate Evidence HCQ Hydroxychloroquine immune Immunosuppressant include induce Inflammation live births low-dose morbidities multicenter Open-label open-label randomized controlled trial outcome Patient patients placental Prednisone Pregnancy Prevent Primary outcome Prognosis progression protocol Randomized controlled trial Randomly Recurrent pregnancy loss Recurrent spontaneous abortion regimen secondary Secondary outcomes spontaneous abortion treat Trial Trial registration Undifferentiated Undifferentiated connective tissue disease Vascular damage women
[DOI] 10.1186/s13063-020-04716-1 PMC 바로가기 [Article Type] Study Protocol

Anticoagulation in critically ill patients on mechanical ventilation suffering from COVID-19 disease, The ANTI-CO trial: A structured summary of a study protocol for a randomised controlled trial

COVID-19 질병으로 고통받는 중환자의 기계적 환기에 대한 항응고, The ANTI-CO 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-09-072022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] 1:1 Abnormalities Administered allergic Anti-Co trial Anticoagulant anticoagulation anticoagulation treatment approval aPTT assumed attending physicians bivalirudin blinded Blinding Clinical improvement Coagulation comparator control group Controlled trial Corporation COVID-19 COVID-19 disease Critically ill patient D-dimer D-dimers dissemination distress dose dropout drug element eligibility eligible exclusion criteria expected experimental group FiO2 for inclusion groups heparin ICU IMPROVE include Inclusion inclusion criteria intervention group intravenously Invasive mechanical ventilation limit Local mechanical ventilation normally distributed number objective on mechanical ventilation outcome P/F P/F ratio PaO2 paO2/fiO2 parallel group parameter participant Patient patients patients with COVID-19 performed Physicians positive power power of 80% Pregnancy Primary outcome protocol randomised randomised controlled trial randomization Randomized receive recruitment Registered registration number respiratory distress Respiratory failure Sample size sample size calculation screened standard treatment status study drug Study protocol subcutaneously subject Taking the mean the patient thrombosis title treated Treatment treatment group Trial registration website
[DOI] 10.1186/s13063-020-04689-1 PMC 바로가기 [Article Type] Letter

Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis

Review article

Published on 2020-09-012022-10-05
Journal: Journal of integrative medicine [Category] SARS, 신약개발,

[키워드] 95% CI 95% confidence interval Adults adverse event adverse events Analysis C-reactive protein Care changes in China Chinese Chinese herbal medicine CHM Cochrane Library collected Computed tomography contagious Continuous control group Controlled trial Course COVID-19 COVID-19 cases criteria CRP current database disease evaluator Evidence Follow-up Google Scholar hazard ratio help IMPROVE Inflammatory inflammatory markers information Infrastructure life-threatening lung CT scan marker Meta-analysis New coronavirus objective Odds ratio outcome Participants Patient peer-reviewed Pneumonia Primary outcome Randomized controlled trial RCT RCTs Result risk risk of bia SARS-CoV-2 screened searched secondary SMD standard care standardized mean difference Study design Symptom systematic review therapy time-to-event analysis Traditional Chinese medicine treat Treatment treatment group Treatment outcome was used were expressed were recorded
[DOI] 10.1016/j.joim.2020.07.008 [Article Type] Review article

Acupressure therapy and Liu Zi Jue Qigong for pulmonary function and quality of life in patients with severe novel coronavirus pneumonia (COVID-19): a study protocol for a randomized controlled trial

중증 신종 코로나바이러스 폐렴(COVID-19) 환자의 폐 기능 및 삶의 질을 위한 지압 요법 및 Liu Zi Jue Qigong: 무작위 대조 시험을 위한 연구 프로토콜

Study Protocol

Published on 2020-08-272022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 2019 novel coronavirus activities activity Acupressure Acupressure therapy addition Admission Adverse adverse events analyst assessor-blinded assessment assessments assigned Barthel Index both groups can be used Chinese Chinese Clinical Trial Registry clinical clinical scale clinical scales complementary Controlled trial COVID-19 Daily discharge Dyspnea effective therapy Efficacy evaluate event Evidence evidence of Hospitalization in both group include intervention group Liu Zi Jue Qigong Liu Zi Jue Qigong exercises Medical Research Council Modified Medical Research Council Dyspnea Scale Novel coronavirus parallel-design Patient Patient Health Questionnaire-9 Scale patients with COVID-19 performed Pneumonia poor prognosis Primary outcome Pulmonary function Qigong Qigong exercise Qigong exercises Quality of life Randomized controlled trial randomized trial Randomly receive recorded recruited registry rehabilitation respiratory Respiratory Symptoms Scale safety evaluation scale secondary outcome Secondary outcomes severe COVID-19 severe disease Study protocol supportive care symptomatic TCMR therapy therapy for COVID-19 Traditional Chinese medicine Traditional Chinese medicine rehabilitation Treatment Trial twice a day Two-arm Wuhan Wuhan, China
[DOI] 10.1186/s13063-020-04693-5 PMC 바로가기 [Article Type] Study Protocol

Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study)

염증이 고조된 SARS-CoV-2 관련 심근 손상에서 심장 및 호흡 기능의 악화를 감소시키는 카나키누맙(Covid-19 심장 손상에서의 카나키누맙: 3개의 C 연구)

Trial Designs

Published on 2020-08-242022-09-10
Journal: Clinical Cardiology [Category] MERS, SARS, 바이오마커, 임상, 진단,

[키워드] anticipated baseline characteristics C‐reactive protein canakinumab cardiac cardiac injury Characteristics Controlled trial COVID‐19 CRP defined Deterioration discharge dysfunction elevated Elevation elevations enrolled evaluate hospital Hospitalized hospitalized COVID‐19 patients hyperlipidemia hypertension Hypothesis IMPROVE Inflammation male median morbidity morbidity and mortality Mortality myocardial injury occur Ordinal Scale outcome Patient Placebo Prevalence Prevent primary endpoint progressive respiratory failure randomization Randomized controlled trial randomized patient reduce Respiratory failure Respiratory function Result SARS‐CoV‐2 SARS‑CoV2 SARS‐CoV2 infection SARS‐CoV‐2 secondary endpoint Seven Time to recovery Treatment troponin troponin T worsening
[DOI] 10.1002/clc.23451 PMC 바로가기 [Article Type] Trial Designs